Bristol Myers Squibb Discontinues Six Clinical Programs, Including NASH-Targeting RNAi Therapy

RNAi Therapy for the Treatment of Nonalcoholic Steatohepatitis (NASH). This therapy is one of the siRNA series drugs targeting Heat Shock Protein 47 (HSP47), which was introduced by Bristol-Myers Squibb in 2016 through an upfront payment of $100 million to Nitto BioPharma, a Japanese biotechnology company. Subsequently, Bristol-Myers Squibb abandoned its RNAi therapy for the treatment of NASH.